Lantheus begins testing new PET agent
Article Thumbnail ImageSeptember 17, 2009 -- Lantheus Medical Imaging of North Billerica, MA, has launched a phase I clinical study to assess the safety, dosimetry, and tolerability of LMI1195, a fluorine-18 small-molecule tracer for imaging cardiac neuronal function in patients undergoing PET imaging.
Member Sign In:
MemberID or E-mail Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  


The study will also evaluate the safety and tolerability of the tracer, gather pharmacokinetic and metabolic data, and assess PET imaging parameters and image quality. LMI1195 is Lantheus' second product using molecular imaging and PET technology for cardiovascular imaging to enter clinical development from its research pipeline, according to the company.

Related Reading

Lantheus signs Australian moly deal, June 15, 2009

PETNet signs supply deal with Lantheus, June 11, 2009

Lantheus completes Definity study enrollment, May 28, 2009

Lantheus signs Mo-99 supply deal, May 20, 2009

Moly crisis leads to price hike for Lantheus technetium generators, May 15, 2009

Copyright © 2009 AuntMinnie.com